To release chronic and
discomfort pain and
to get patients' and
their family's smile back

About AlphaNavi Pharma

Our mission to get patients' and their family's smiles back through the research & development of innovative novel drugs

News

2021/05/11
- information
AlphaNavi Pharma Inc., Announces Initiation of a Phase 1/2 Clinical Trial of ANP-230 in Patients with Familial Infantile Episodic Limb Pain
AlphaNavi Pharma Inc. (Headquarter: Sakyo-ku, Kyoto, Japan; CEO: Yoshihiro Oyamada) today announced the initia …
2020/06/05
- information
AlphaNavi Pharma Inc., was introduced in the case study of leading university-originated venture businesses’ efforts for team building, published by the Ministry of Economy, Trade, and Industry.
AlphaNavi Pharma Inc., (Head Office: Kyoto, Japan; CEO: Yoshihiro Oyamada), which is a start-up company to dev …
2020/05/12
- information
“Study of a novel drug for the familial episodic infantile limb pain syndrome” was chosen by AMED as Cyclic Innovation for Clinical Empowerment (CiCLE) program and was initiated collaboratively with Kyoto University and Akita University.
AlphaNavi Pharma Inc., (Head Office: Kyoto, Japan; CEO: Yoshihiro Oyamada; hereinafter referred to as “A …